ADVERTISEMENT

Orchid Pharma Q2 Results Review - Inline Revenue, Gross Margins Come Higher: Systematix

The brokerage recommends a 'Buy' with a target price of Rs 1,823 based on 45 times PE /multiple (50 times earlier).

<div class="paragraphs"><p>Close up tablets arranged for photograph. (Source: pxhere)</p></div>
Close up tablets arranged for photograph. (Source: pxhere)
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
To continue reading this story
Subscribe to Unlock & Enjoy your 
Subscriber-Only
 benefits

Choose a plan

Renews automatically. Cancel anytime.
Still Not convinced ? Know More